Question Bank › Sequential re-rating

Sequential re-rating

Sequential re-rating: management describes the same offering landing bigger the second and third time around

Calls Tested
498
Answered YES
7
Hit Rate
1.4%
rare by design

Accuray Incorporated (ARAY) — this company's answers

NO on the Q4 2016 call 2016-08-17 B
The model's full reasoning — Q4 2016 call → NO我们根据提供的财报电话会议记录来判断。管理层是否描述了公司同类业务(如订单、合同等)的规模在逐步扩大?需要寻找管理层自己的表述,对比过去,且是当前现实,并表明这种扩大是近期发生的,未来还会继续。 在记录中,Josh Levine提到:“In the fourth quarter, greater than 50% of TomoTherapy orders were in single and dual vault settings, demonstrating the market's increasing recognition of the workhorse capabilities and industry-leading reliability of this product. TomoTherapy Systems are increasingly being placed outside of multi-bunker academic settings, which represents continued expansion of the selling opportunity we have with TomoTherapy.” 这说的是TomoTherapy订单更多出现在单/双vault设置,即非多bunker学术环境,这表示销售机会扩大,但并未明确说单个订单规模变大。 还有:“Additionally, we are also shifting resources to several key sustaining engineering projects...” 不相关。 关于多系统订单:“We have more -- we recorded more multi-system sales in the last fiscal year than any time in our history. It speaks to a lot of the work that we've done in regards to strategic accounts selling and positioning ourselves with larger groups and integrated delivery networks and health systems. And I expect that to continue.” 这里提到多系统销售比历史上任何时候都多,但这是指数量更多,还是单个订单更大?可能是指多系统订单的数量增加,但并未明确说每个订单的规模在逐步扩大。而且“more multi-system sales”可能是指更多笔多系统交易,而不是每笔交易更大。 还有关于NHS订单:“This was largest order in the company's history from a single customer and an important strategic win for us.” 但这是单个记录,管理层是否将其视为上升趋势的一部分?在回答中,Josh说:“It's important to note that we generated our record fourth quarter gross orders despite not recording a large domestic multi-system order that we referenced earlier and had expected close during our fiscal third quarter. The customer for that order has informed us that they now expect to place several individual orders in fiscal 2017 versus one large one, and in fact, the first of these systems has already gone into backlog in Q1 of the new fiscal year.” 这里提到一个大型国内多系统订单被拆分成几个单独订单,这实际上可能意味着单个订单规模变小了,而不是变大。 另外,关于Radixact和Onrad,都是新产品,但并未提及订单规模扩大。 管理层提到“multi-system orders”是重点,但并未明确说这些订单的规模在逐步增大。相反,有提到定价压力,但那是关于价格。 在回答分析师问题时,Josh说:“We have more -- we recorded more multi-system sales in the last fiscal year than any time in our history.” 这可能是说多系统销售的数量增加,但并未说每个订单的规模增加。而且“more”可能指数量。 此外,关于“backlog”增长8%,但那是总量。 因此,没有明确的管理层表述表明“同类业务的单位规模在逐步扩大”。相反,有提到大型订单被拆分,以及定价压力。所以答案应为NO。

← Back to the full ARAY analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE — that is, does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon as a present-tense reality: the unit size of the company's own repeatable business is escalating. Any genuine expression of this counts, and the form varies widely across industries. For example — management noting that the average size of new orders, contracts, or deals has stepped up versus what the company used to sign; that its newest customers are starting at a level its early customers took years to reach, or are entering at broader scope from the outset; that where it once sold a single unit, department, site, or product, the same type of buyer now commits to many at once; that follow-on commitments from the same counterparties are arriving at multiples of the initial ones; that the projects, programs, or engagements it is now being awarded are individually larger or longer-dated than its historical norm; that initial commitments increasingly arrive as full deployments rather than as trials; or that the largest single piece of business in the company's history was just signed and management presents it as part of an upward drift in deal size rather than an isolated event. Three things should come through in management's own voice. First, A COMPARISON AGAINST THE COMPANY'S OWN RECENT PAST — management contrasts the size or scope of what it is landing now with what it was landing before for substantially the same offering, so the point is escalation of unit size, not merely more units or a good quarter. Second, ALREADY REAL AND RECURRING — the larger instances are things actually signed, ordered, awarded, or begun in the recent period, and management conveys a pattern rather than one exceptional event; a single record deal counts only if management frames it as part of an upward drift in the size of what the company is winning. Third, EARLY — management conveys, directly or plainly in substance, that this escalation is recent enough that the reported results still largely reflect the smaller-instance era, and that further instances at the new, larger size are already forming, in negotiation, or expected to keep arriving. Answer NO if management simply reports strong demand, more customers, higher revenue, or a good quarter without conveying that the individual size of what it lands has grown versus its own past. NO if the growth described comes purely from volume — more of the same-sized business — or from price increases on unchanged scope. NO if larger deals are only hoped for, targeted, sitting in a pipeline, or described as an ambition to move upmarket. NO if the only evidence is one outsized transaction that management itself treats as exceptional or non-repeating. NO if large engagements have always been the ordinary unit of this company's business and nothing about their size has changed. NO if management is chiefly describing deal sizes shrinking, scopes being cut, customers downsizing commitments, or contracts being renegotiated smaller. NO if the escalation is already mature and fully reflected in current results, with nothing further ahead. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+

How the model reasoned

AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.

More from the question bank

Answers go deeper than the scriptFresh evidence outrunning the reported numbeSold before it existsCustomers coming back on their ownPromise already turning into factThe open question just closedAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.